Latest Breaking News On - Protara therapeutics - Page 8 : comparemela.com

Medical Second Opinion Global Market to Register Stunning Growth at a CAGR of ~17% by 2028

/PRNewswire/ DelveInsight s Medical Second Opinion Market Insights report provides the current and forecast market analysis, individual leading medical.

United statesCity ofUnited kingdomPrnewswire delveinsightExpressi ontherapeuticsKlus pharmaAstellas pharmaTaizhou hanzhongTakara bioShruti thakurInnocare pharmaEmtora biosciencesTransthera biosciencesAthira pharmaBristol myers squibbInmune bio

DelveInsight Business Research, LLP: Medical Second Opinion Global Market to Register Stunning Growth at a CAGR of ~17% by 2028

DelveInsight Business Research, LLP: Medical Second Opinion Global Market to Register Stunning Growth at a CAGR of ~17% by 2028
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesCity ofUnited kingdomAthira pharmaExpressi ontherapeuticsEli lillyTransthera biosciencesPrnewswire delveinsightTaizhou hanzhongInmune bioKlus pharmaBristol myers squibbEmtora biosciencesAstellas pharmaShruti thakurOcellaris pharma

Protara Therapeutics, Inc (NASDAQ:TARA) Short Interest Update

Protara Therapeutics, Inc. (NASDAQ:TARA – Get Free Report) was the recipient of a large drop in short interest during the month of July. As of July 31st, there was short interest totalling 77,700 shares, a drop of 28.5% from the July 15th total of 108,600 shares. Based on an average daily trading volume, of 34,000 […]

Virtu financialProtara therapeutics incPrivium fund management united kingdom ltdProtara therapeutics company profileRenaissance technologiesPrivium fund managementProtara therapeuticsGet free reportFund management united kingdom ltdProtara therapeutics dailyNasdaq tara

Short Interest in Protara Therapeutics, Inc (NASDAQ:TARA) Decreases By 28 5%

Protara Therapeutics, Inc. (NASDAQ:TARA – Get Free Report) saw a significant decline in short interest in July. As of July 31st, there was short interest totalling 77,700 shares, a decline of 28.5% from the July 15th total of 108,600 shares. Approximately 0.9% of the shares of the stock are short sold. Based on an average […]

Virtu financialProtara therapeutics incPrivium fund management united kingdom ltdPrivium fund managementRenaissance technologiesProtara therapeuticsGet free reportFund management united kingdom ltdProtara therapeutics dailyNasdaq tara

Bladder Cancer Market Likely To Exhibit Substantial Growth, Assesses Delveinsight | Leading Companies - Ciclomed, Bristol-Myers Squibb, Cg Oncology, M

Bladder Cancer Market Likely To Exhibit Substantial Growth, Assesses Delveinsight | Leading Companies - Ciclomed, Bristol-Myers Squibb, Cg Oncology, M
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesFidia farmaceuticiBristol myers squibbEli lillyPrnewswire delveinsightAstellas pharma inc incyte corporationJanssen research developmentTaiho oncology incMerck sharp dohmeIncyte corporationUrogen pharma ltdCg oncology incOncology incSeagen incDgene inc